（编辑 袁冠琳） 证券日报网讯 1月29日，广誉远在互动平台回答投资者提问时表示，公司目前在任董事及高级管理人员 均各司其职，严格根据相关法律法规履职尽责，各项工作均在有序推进，不存在任何应披露未披露事 项。公司已根据相关法律法规及时发布《关于董事会延期换届及部分独立董事任期届满的提示性公 告》，表述准确、完整，公司正积极推动换届选举工作。 ...

证券日报网讯1月29日，广誉远（600771）在互动平台回答投资者提问时表示，公司会严格按照相关法 律法规开展业务并及时履行信息披露。 ...

证券日报网讯1月29日，广誉远（600771）在互动平台回答投资者提问时表示，公司一切生产、经营活 动均有序开展，具体经营情况，请关注公司公告。 ...

证券日报网讯1月29日，广誉远（600771）在互动平台回答投资者提问时表示，独家产品加味龟龄集药 酒，公司已在线上线下（300959）布局售卖且不断优化渠道，根据相关法规该药酒不可进行广告宣传， 但公司结合自身情况，持续对公司品牌、远字牌龟龄集保健酒、定坤丹(OTC)等通过高铁冠名、平台传 播、官媒推广等多种途径持续曝光，不断增加知名度和影响力，持续扩大品牌声量。 ...

证券日报网讯1月29日，广誉远（600771）在互动平台回答投资者提问时表示，公司已于2026年1月17日 披露《关于董事会延期换届及部分独立董事任期届满的提示性公告》，目前公司董事会换届选举工作尚 在筹备中，不存在提名的独立董事人选未通过资格审查的情形。公司将积极推进相关工作，并及时履行 信息披露义务。 ...

证券之星消息，1月29日中药板块较上一交易日上涨0.98%，片仔癀领涨。当日上证指数报收于4157.98， 上涨0.16%。深证成指报收于14300.08，下跌0.3%。中药板块个股涨跌见下表： 从资金流向上来看，当日中药板块主力资金净流入1210.05万元，游资资金净流出9243.6万元，散户资金 净流入8033.56万元。中药板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 600436 | 片仔瘦 | 2.4216 | 11.07% | -9063.85万 | -4.15% | -1.51 Z | -6.92% | | 600085 | 同仁堂 | 5722.98万 | 9.44% | -1391.28万 | -2.30% | -4331.71万 | -7.15% | | 600771 | 广营远 | 4647.58万 | 12.43% | -2690.82万 | -7.20% | - ...

Core Viewpoint - The audit of Guangyuyuan Traditional Chinese Medicine Co., Ltd. from 2016 to 2018 revealed significant deficiencies in the auditing processes, leading to insufficient evidence and inappropriate conclusions regarding revenue recognition and sales expenses [1][2][3][4][5] Group 1: Revenue Audit Issues - The audit tests for revenue from 2016 to 2018 were inadequately executed, resulting in insufficient audit evidence [1] - Interviews conducted during the audit did not adequately consider the impact of return and payment terms on revenue recognition, nor did they address discrepancies in reported sales figures [1][2] - Contract checks were superficial, failing to identify critical clauses affecting revenue recognition and not verifying the actual inventory and sales situation of downstream commercial companies [2] - Sampling procedures for document verification were not followed as planned, leading to incomplete data and inconsistent information across business documents [2][3] - The audit did not adequately address issues related to returns, including incomplete documentation and non-compliance with contractual return conditions [3] Group 2: Sales Expense Audit Issues - The audit of advertising expenses in 2018 lacked thorough verification of contracts and supporting documents, leading to unsubstantiated conclusions about the accuracy of expense recognition [4] Group 3: Regulatory Violations and Consequences - The auditors' actions violated several auditing standards and regulations, leading to a warning letter issued by the Beijing Securities Regulatory Bureau [5] - The auditors involved, including Jiang Shuxia, Wang Xingjie, and Qiao Xin, are held primarily responsible for the identified issues and face regulatory measures [5]

Core Viewpoint - Guangyuyuan has confirmed that the board of directors' re-election process is in accordance with regulatory rules and will not affect the company's normal operations [1] Group 1 - The company announced on January 17, 2026, that the board of directors' re-election work has been completed [1] - Zhao Xuanmin will continue to perform his duties as an independent director and in various committees until the re-election is finalized [1] - The terms of the eighth board members and senior management will be extended accordingly [1]

Group 1 - The core issue involves investor claims against Guangyuyuan (600771) for false statements, with ongoing legal proceedings initiated by attorney Xu Feng [1] - The company was found to have misrepresented its "buyout sales" model in annual reports from 2016 to 2021, leading to premature revenue recognition and incorrect handling of sales expenses [1] - The administrative penalty from the China Securities Regulatory Commission (CSRC) was issued on April 11, 2024, confirming the violations [1] Group 2 - Investors who purchased Guangyuyuan stock between March 21, 2017, and December 29, 2023, are eligible to file claims [2] - Attorney Xu Feng is also handling claims for Tianwo Technology (002564), which has seen successful settlements for some investors [2] - Tianwo Technology was found to have false records in its periodic reports and failed to disclose related party transactions and the use of raised funds [3][4]

Group 1 - The company's eighth board of directors will expire on January 17, 2026, and the board's election work is still in preparation, leading to a postponement of the board's renewal [2] - To ensure continuity and stability, the terms of the board's special committees and senior management will be extended accordingly until the board's election is completed [2] - The current independent director, Zhao Xuanmin, has served since January 15, 2020, and will reach the six-year limit for continuous service, but will continue to fulfill his duties until new independent directors are elected [3] Group 2 - The postponement of the board's renewal will not affect the company's normal operations, and the company will actively promote related work and fulfill its information disclosure obligations in a timely manner [4]